BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35690817)

  • 1. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
    Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M
    Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
    Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
    Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
    Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
    Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
    Russo M; Liu K; Chan C
    Reprod Biol Endocrinol; 2020 Jun; 18(1):59. PubMed ID: 32503566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients.
    Sonigo C; Sermondade N; Calvo J; Benard J; Sifer C; Grynberg M
    Eur J Obstet Gynecol Reprod Biol X; 2019 Oct; 4():100049. PubMed ID: 31673686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
    Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
    Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
    Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
    Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
    Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
    J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
    Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
    Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy.
    Massarotti C; Stigliani S; Gazzo I; Lambertini M; Anserini P
    ESMO Open; 2023 Aug; 8(4):101597. PubMed ID: 37421801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
    Cheng ZX; Kong G; Zhang CL; Zhao YN
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial.
    Bülow NS; Skouby SO; Warzecha AK; Udengaard H; Andersen CY; Holt MD; Grøndahl ML; Nyboe Andersen A; Sopa N; Mikkelsen ALE; Pinborg A; Macklon NS
    Hum Reprod; 2022 Jan; 37(2):309-321. PubMed ID: 34792133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
    Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
    Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
    Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
    Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
    Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients.
    Cavagna F; Pontes A; Cavagna M; Dzik A; Donadio NF; Portela R; Nagai MT; Gebrim LH
    Curr Oncol; 2018 Dec; 25(6):e527-e532. PubMed ID: 30607119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.